Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methlice-CT is a topical combination lotion marketed by Alicia Healthcare, an Indian generic pharmaceutical company. It is primarily indicated for the treatment of scabies, caused by the mite *Sarcoptes scabiei*, and pediculosis (head lice infestations). The formulation typically contains permethrin, a synthetic pyrethroid that acts as a potent neurotoxin to parasites by binding to voltage-gated sodium channels and slowing their inactivation, leading to prolonged depolarization, paralysis, and death of the organism. It also contains cetrimide, a quaternary ammonium compound that functions as an antiseptic and surfactant, aiding in the cleansing of the skin and potentially enhancing the penetration of the active scabicide. Methlice-CT is distributed as a commercial generic product within the Indian pharmaceutical market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Methlice-CT.